Corporate Banner
Satellite Banner
Next Gen Sequencing
Scientific Community
 
Become a Member | Sign in
Home>Resources>Application Notes>This Application Note
  Application Notes
Scientific News
New Neurodevelopmental Syndrome Identified
Study pinpoints underlying genetic mutations, raising hopes for targeted therapies.
Uncovering Hidden Genomic Alterations that Drive Cancers
Tested on large tumor genomics database, REVEALER method allows researchers to connect genomics to cell function.
Gene Behind Rare Childhood Syndrome Identified
Online activism by one patient’s mother spurred research collaboration which led to the identification of a new genetic syndrome.
Resilience Project Identifies Rare Unaffected Individuals
Researchers from Mount Sinai and Sage Bionetworks report analysis of nearly 600,000 genomes for resilience project.
Rare DNA Will Have Nowhere To Hide
Two National Institutes of Health grants back Rice University effort to develop new diagnostics.
Virus Causing Tilapia Die-Offs Identified
Discovery of the virus causing Tilapia die-offs in Israel and Ecuador points the way to protecting a fish that feeds multitudes.
Children With Cancer To Get New Gene Test
Pilot study will sequence 81 cancer genes in children’s tumours to help personalise cancer treatment.
How The Bat Got Its Wings
Finding may provide clues to human limb development and malformations.
Lupus Study Shows Precision Medicine’s Potential to Define the Genetics of Autoimmune Disease
Researchers at UT Southwestern have used next-generation DNA sequencing technology to identify more than 1,000 gene variants that affect susceptibility to SLE.
Illuminating the Broad Spectrum of Disease
PRISM efficiently tests drug compounds in multiple cell lines simultaneously, accelerating discovery of targeted therapies in the service of precision medicine.
Scroll Up
Scroll Down

Sequence-Specific DNA Assay
Bookmark and Share

Molecular Devices

Measurement of specific DNA sequences can be achieved using the Threshold® System. Biotinylated and fluoresceinated oligonucleotide probes specific to the target sequence to be measured are used with the Immuno Ligand Assay (ILA) kit components. The probes are chosen so that they both anneal to the same strand of the target, adjacent to each other. DNA samples to be measured are digested with an appropriate restriction enzyme to liberate the target sequence on a small DNA fragment. The digested DNA is denatured in the presence of an excess of the biotinylated and fluoresceinated probes. The probes and denatured target are allowed to anneal, generating probe-target hybrids. These probe-target hybrids are captured on the biotinylated Threshold sticks using the ILA capture reagent (streptavidin) which binds to the biotinylated probe. The captured probe-target hybrids are then detected and quantitated using the ILA enzyme reagent (antifluorescein- urease conjugate) which binds to the fluoresceinated probe. This application note is intended as a guide and does not represent a validation of this assay, nor necessarily the optimal performance parameters for all probe and target DNA combinations.



Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!